

# The genotype of MHL1 identifies a subgroup of follicular lymphoma patients that do not benefit from doxorubicin: FIL-FOLL05 STUDY

428 follicular lymphoma patients  
FOLL05 prospective trial



First line therapy comparison of standard-of-care regimens

R-CVP

rituximab  
cyclophosphamide  
vincristine  
prednisone

R-CHOP

rituximab  
cyclophosphamide  
doxorubicin  
vincristine  
prednisone

R-FM

rituximab  
fludarabine  
mitoxantrone

Effect of polymorphism genotyped on time to treatment failure (TTF)

*FCGR2A*

No effect

No effect

No effect

pooled analysis treatment arms  $p=0.742$

*FCGR3A*

No effect

No effect

No effect

pooled analysis treatment arms  $p=0.252$

*MLH1*

No effect

**$p=0.001$**

No effect